Global Human Chorionic Gonadotropin (hCG) Market Expected to Reach $1,239 Million by 2025

According to a new report published by Allied Market Research, titled,"Human Chorionic Gonadotropin (hCG) Market by Technology, Therapeutic Area, and End User: Global Opportunity Analysis and Industry Forecast, 2018 - 2025", the global human chorionic gonadotropin (hCG) market generated revenue of $688 million in 2017 and is expected to reach $1,239 million by 2025, registering a CAGR of 7.6% from 2018 to 2025.

Rise in incidence of infertility-related problems in both the genders drive the growth of the global hCG market. In addition, upsurge in the adoption of hCG hormone in pain management and weight loss propel the market growth. Furthermore, incorporation of recombinant technology for the development of hCG is anticipated to offer lucrative opportunities for the market growth in the near future.

Based on technology, the market is divided into natural source extraction and recombinant technology. The recombinant technology segment is expected to register the highest growth rate during the forecast period. However, the natural source extraction segment dominated the global market in 2017 and is anticipated to remain dominant throughout the forecast period. This is attributed to easy and low-cost availability of hCG from pregnant womens urine and placenta cells.

Based on the therapeutic area, the global market is classified into female infertility treatment, oligospermic treatment, male hypogonadism, and others. Male hypogonadism segment is anticipated to witness highest growth rate in the global market, owing to high susceptibility of geriatric population to hypogonadism. However, female infertility treatment dominated the therapeutic area segment in 2017, owing to surge in female infertility-related problems such as polycystic ovaries, hormonal imbalance, and others.

Key Findings of the Human Chorionic Gonadotropin (hCG) Market:

• The oligospermic treatment segment registered the second highest CAGR during the forecast period among the therapeutic area.
• The fertility clinics end user segment dominated the market, accounting for half of the total share in 2017.
• North America dominated the market, accounting for maximum share of the overall market in 2017.
• Germany was the highest contributor to the European human chorionic gonadotropin (hCG) market in 2017 and is expected to maintain this dominance throughout the forecast period.

Asia-Pacific is expected to witness the highest growth rate throughout the forecast period, due to its high population base, surge in disposable income, and rise in awareness toward infertility treatment procedures. In addition, rise in fertility tourism in Asia-Pacific countries such as Thailand and Malaysia boosts the market growth.

The major companies profiled in the report include Bristol Myers Squibb Company, Merck & Co., Inc., Ferring B.V., Fresenius Kabi AG, Cigna, Sun Pharmaceutical Industries Ltd, Lee BioSolutions Inc., Sanzyme, Scripps Laboratories, and Lupin AB. The other players operating in the global human chorionic gonadotropin (hCG) market include Kamiya Biomedical Company, Intas Pharmaceuticals, Prospec-Tany Technogene Ltd., Cipla Limited, Biocare Medical, LLC, MyBioSource, Zydus Cadila, and Life Medicare & Biotech Pvt. Ltd.